Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems

Core Viewpoint - VolitionRx Limited has expanded its supply agreement with Fujifilm Vet Systems in Japan to include an automated version of its Nu.Q® Vet Cancer Test, aiming for a launch in summer 2025 [1][2][3] Company Overview - Volition is a multi-national epigenetics company focused on advancing the science of epigenetics and improving outcomes for people and animals through early detection of diseases [7][8] - The company is developing cost-effective blood tests for diagnosing and monitoring various diseases, including cancers [8] Product Details - The Nu.Q® Vet Cancer Test is designed for regular check-ups of older dogs (seven years and older) or younger high-risk breeds, priced at an average of $11 per test for central lab testing [4] - The test is non-invasive and aims to aid in early cancer detection, which is crucial as cancer is the leading cause of adult canine deaths [3][4] Market Opportunity - There are approximately seven million pet dogs in Japan, presenting a significant revenue opportunity for Volition through its partnership with Fujifilm Vet Systems, a leading provider of diagnostic tests in the country [2] - Since the launch of the Nu.Q® Vet Cancer Test in July 2024, over 1,000 veterinary hospitals in Japan have registered to use the test, indicating strong demand [2][3] Partnership Dynamics - Fujifilm Vet Systems will validate and verify the automated platform for canine cancer screening, enhancing the efficiency and throughput of the testing process [1][2] - The agreement allows Fujifilm Vet Systems to sell and perform the Nu.Q® Vet Cancer Test across its network of central reference laboratories in Japan [3]